Skip to main content
Top
Published in: Sleep and Breathing 1/2012

01-03-2012 | Hypoxia Conference

Respiratory regulation in narcolepsy

Author: Fang Han

Published in: Sleep and Breathing | Issue 1/2012

Login to get access

Abstract

Introduction

Narcolepsy is a debilitating sleep disorder characterized by excessive daytime sleepiness, cataplexy and intrusive REM sleep. Deficits in endogenous orexins are a major pathogenic component of the disease. This disorder is also associated with the gene marker, HLADQB1*0602. An increased prevalence of sleep apnea in narcolepsy suggested interactions among ventilatory chemosensitivity, narcolepsy-cataplexy, and sleep apnea.

Results

Evidence from animal studies using orexin knockout mice and focal microdialysis of an orexin receptor antagonist demostrated that orexins are also contributed to respiratory regulation in a vigilance state-dependent manner, as animals with orexins dysregulation have attenuated hypercapnic ventilatory responses predominately in wakefulness, which is consistent with the notion that the activity of orexinergic neurons is higher during wake than sleep periods. Human model of hypocretin deficiency is patients with narcolepsy-cataplexy. In contrast to findings suggested by animal studies, we found significant decrease in hypoxic responsiveness but not in hypercapnic responsiveness in narcoleptics, and further analysis indicated that decreased ventilatory responses to hypoxia in human narcolepsy-cataplexy is in relation to HLA-DQB1*0602 status, not hypocretin deficiency.

Conclusion

Unlike in mouse, hypocretin-1 is not a major factor contributing to chemoresponsiveness in human. Species differences may exist.
Literature
1.
go back to reference Weil JV (2003) Variation in human ventilatory control-genetic influence on the hypoxic ventilatory response. Respir Physiol Neurobiol 135:239–246PubMedCrossRef Weil JV (2003) Variation in human ventilatory control-genetic influence on the hypoxic ventilatory response. Respir Physiol Neurobiol 135:239–246PubMedCrossRef
2.
go back to reference Han F, Strohl KP (2000) Inheritance of ventilatory behavior in rodent models. Respir Physiol 121:247–256PubMedCrossRef Han F, Strohl KP (2000) Inheritance of ventilatory behavior in rodent models. Respir Physiol 121:247–256PubMedCrossRef
3.
go back to reference Mieda M, Sakurai T (2009) Integrative physiology of orexins and orexin receptors. CNS Neurol Disord Drug Targets 8:281–295PubMedCrossRef Mieda M, Sakurai T (2009) Integrative physiology of orexins and orexin receptors. CNS Neurol Disord Drug Targets 8:281–295PubMedCrossRef
4.
go back to reference Lin L, Faraco J, Li R, Kadotani H, Rogers W, Lin X, Qiu X, de Jong PJ, Nishino S, Mignot E (1999) The sleep disorder canine narcolepsy is caused by a mutation in the hypocretin (orexin) receptor 2 gene. Cell 98:365–376PubMedCrossRef Lin L, Faraco J, Li R, Kadotani H, Rogers W, Lin X, Qiu X, de Jong PJ, Nishino S, Mignot E (1999) The sleep disorder canine narcolepsy is caused by a mutation in the hypocretin (orexin) receptor 2 gene. Cell 98:365–376PubMedCrossRef
5.
go back to reference Chemelli RM, Willie JT, Sinton CM, Elmquist JK, Scammell T, Lee C, Richardson JA, Williams SC, Xiong Y, Kisanuki Y, Fitch TE, Nakazato M, Hammer RE, Saper CB, Yanagisawa M (1999) Narcolepsy in orexin knockout mice: molecular genetics of sleep regulation. Cell 98:437–451PubMedCrossRef Chemelli RM, Willie JT, Sinton CM, Elmquist JK, Scammell T, Lee C, Richardson JA, Williams SC, Xiong Y, Kisanuki Y, Fitch TE, Nakazato M, Hammer RE, Saper CB, Yanagisawa M (1999) Narcolepsy in orexin knockout mice: molecular genetics of sleep regulation. Cell 98:437–451PubMedCrossRef
6.
go back to reference Nishino S, Ripley B, Overeem S, Lammers GJ, Mignot E (2000) Hypocretin (orexin) deficiency in human narcolepsy. Lancet 355:39–40PubMedCrossRef Nishino S, Ripley B, Overeem S, Lammers GJ, Mignot E (2000) Hypocretin (orexin) deficiency in human narcolepsy. Lancet 355:39–40PubMedCrossRef
7.
go back to reference Peyron C, Faraco J, Rogers W, Ripley B, Overeem S, Charnay Y, Nevsimalova S, Aldrich M, Reynolds D, Albin R, Li R, Hungs M, Pedrazzoli M, Padigaru M, Kucherlapati M, Fan J, Maki R, Lammers GJ, Bouras C, Kucherlapati R, Nishino S, Mignot E (2000) A mutation in a case of early onset narcolepsy and a generalized absence of hypocretin peptides in human narcoleptic brains. Nat Med 6:991–997PubMedCrossRef Peyron C, Faraco J, Rogers W, Ripley B, Overeem S, Charnay Y, Nevsimalova S, Aldrich M, Reynolds D, Albin R, Li R, Hungs M, Pedrazzoli M, Padigaru M, Kucherlapati M, Fan J, Maki R, Lammers GJ, Bouras C, Kucherlapati R, Nishino S, Mignot E (2000) A mutation in a case of early onset narcolepsy and a generalized absence of hypocretin peptides in human narcoleptic brains. Nat Med 6:991–997PubMedCrossRef
8.
go back to reference Lin L, Jin L, Kimura A, Carrington M, Mignot E (1997) DQ microsatellite association studies in three ethnic groups. Tissue Antigens 50:507–520PubMedCrossRef Lin L, Jin L, Kimura A, Carrington M, Mignot E (1997) DQ microsatellite association studies in three ethnic groups. Tissue Antigens 50:507–520PubMedCrossRef
9.
go back to reference Nakamura A, Zhang W, Yanagisawa M, Fukuda Y, Kuwaki T (2007) Vigilance state-dependent attenuation of hypercapnic chemoreflex and exaggerated sleep apnea in orexin knockout mice. J Appl Physiol 102:241–248PubMedCrossRef Nakamura A, Zhang W, Yanagisawa M, Fukuda Y, Kuwaki T (2007) Vigilance state-dependent attenuation of hypercapnic chemoreflex and exaggerated sleep apnea in orexin knockout mice. J Appl Physiol 102:241–248PubMedCrossRef
10.
go back to reference Deng BS, Nakamura A, Zhang W, Yanagisawa M, Fukuda Y, Kuwaki T (2007) Contribution of orexin in hypercapnic chemoreflex: evidence from genetic and pharmacological disruption and supplementation studies in mice. J Appl Physiol 103:1772–1779PubMedCrossRef Deng BS, Nakamura A, Zhang W, Yanagisawa M, Fukuda Y, Kuwaki T (2007) Contribution of orexin in hypercapnic chemoreflex: evidence from genetic and pharmacological disruption and supplementation studies in mice. J Appl Physiol 103:1772–1779PubMedCrossRef
11.
12.
go back to reference Plazzi G, Serra L, Ferri R (2008) Nocturnal aspects of narcolepsy with cataplexy. Sleep Med Rev 12:109–128PubMedCrossRef Plazzi G, Serra L, Ferri R (2008) Nocturnal aspects of narcolepsy with cataplexy. Sleep Med Rev 12:109–128PubMedCrossRef
13.
go back to reference Dias MB, Li A, Nattie E (2010) The orexin receptor 1 (OX1R) in the rostral medullary raphe contributes to the hypercapnic chemoreflex in wakefulness, during the active period of the diurnal cycle. Respir Physiol Neurobiol 170:96–102PubMedCrossRef Dias MB, Li A, Nattie E (2010) The orexin receptor 1 (OX1R) in the rostral medullary raphe contributes to the hypercapnic chemoreflex in wakefulness, during the active period of the diurnal cycle. Respir Physiol Neurobiol 170:96–102PubMedCrossRef
14.
go back to reference Dias MB, Li A, Nattie EE (2009) Antagonism of orexin receptor-1 in the retrotrapezoid nucleus inhibits the ventilatory response to hypercapnia predominantly in wakefulness. J Physiol 587:2059–2067PubMedCrossRef Dias MB, Li A, Nattie EE (2009) Antagonism of orexin receptor-1 in the retrotrapezoid nucleus inhibits the ventilatory response to hypercapnia predominantly in wakefulness. J Physiol 587:2059–2067PubMedCrossRef
15.
go back to reference Li A, Nattie EE (2010) Antagonism of rat orexin receptors by almorexant attenuates central chemoreception in wakefulness in the active period of the diurnal cycle. J Physiol 588:2935–2944PubMedCrossRef Li A, Nattie EE (2010) Antagonism of rat orexin receptors by almorexant attenuates central chemoreception in wakefulness in the active period of the diurnal cycle. J Physiol 588:2935–2944PubMedCrossRef
16.
go back to reference Kuwaki T (2008) Orexinergic modulation of breathing across vigilance states. Respir Physiol Neurobiol 164:204–212PubMedCrossRef Kuwaki T (2008) Orexinergic modulation of breathing across vigilance states. Respir Physiol Neurobiol 164:204–212PubMedCrossRef
17.
go back to reference Kuwaki T, Li A, Nattie E (2010) State-dependent central chemoreception: a role of orexin. Respir Physiol Neurobiol 173:223–229PubMedCrossRef Kuwaki T, Li A, Nattie E (2010) State-dependent central chemoreception: a role of orexin. Respir Physiol Neurobiol 173:223–229PubMedCrossRef
18.
go back to reference Nattie E, Li A (2010) Central chemoreception in wakefulness and sleep: evidence for a distributed network and a role for orexin. J Appl Physiol 108:1417–1424PubMedCrossRef Nattie E, Li A (2010) Central chemoreception in wakefulness and sleep: evidence for a distributed network and a role for orexin. J Appl Physiol 108:1417–1424PubMedCrossRef
19.
go back to reference Han F, Mignot E, Wei YC, Dong SX, Li J, Lin L, An P, Wang LH, Wang JS, He MZ, Gao HY, Li M, Gao ZC, Strohl KP (2010) Ventilatory chemoresponsiveness, narcolepsy-cataplexy, and HLA-DQB1*0602 status. Eur Respir J 36:577–583PubMedCrossRef Han F, Mignot E, Wei YC, Dong SX, Li J, Lin L, An P, Wang LH, Wang JS, He MZ, Gao HY, Li M, Gao ZC, Strohl KP (2010) Ventilatory chemoresponsiveness, narcolepsy-cataplexy, and HLA-DQB1*0602 status. Eur Respir J 36:577–583PubMedCrossRef
20.
go back to reference Stornetta RL (2008) Identification of neurotransmitters and co-localization of transmitters in brainstem respiratory neurons. Respir Physiol Neurobiol 164(1–2):18–27PubMedCrossRef Stornetta RL (2008) Identification of neurotransmitters and co-localization of transmitters in brainstem respiratory neurons. Respir Physiol Neurobiol 164(1–2):18–27PubMedCrossRef
22.
23.
go back to reference Kayaba Y, Nakamura A, Kasuya Y, Ohuchi T, Yanagisawa M, Komuro I, Fukuda Y, Kuwaki T (2003) Attenuated defense response and low basal blood pressure in orexin knockout mice. Am J Physiol Regul Integr Comp Physiol 285:R581–R593PubMed Kayaba Y, Nakamura A, Kasuya Y, Ohuchi T, Yanagisawa M, Komuro I, Fukuda Y, Kuwaki T (2003) Attenuated defense response and low basal blood pressure in orexin knockout mice. Am J Physiol Regul Integr Comp Physiol 285:R581–R593PubMed
24.
go back to reference Young JK, Wu M, Manaye KF, Kc P, Allard JS, Mack SO, Haxhiu MA (2005) Orexin stimulates breathing via medullary and spinal pathways. J Appl Physiol 98:1387–1395PubMedCrossRef Young JK, Wu M, Manaye KF, Kc P, Allard JS, Mack SO, Haxhiu MA (2005) Orexin stimulates breathing via medullary and spinal pathways. J Appl Physiol 98:1387–1395PubMedCrossRef
25.
go back to reference Williams RH, Burdakov D (2008) Hypothalamic orexins/hypocretins as regulators of breathing. Expert Rev Mol Med 10:e28PubMedCrossRef Williams RH, Burdakov D (2008) Hypothalamic orexins/hypocretins as regulators of breathing. Expert Rev Mol Med 10:e28PubMedCrossRef
26.
go back to reference Gestreau C, Bévengut M, Dutschmann M (2008) The dual role of the orexin/hypocretin system in modulating wakefulness and respiratory drive. Curr Opin Pulm Med 14:512–518PubMedCrossRef Gestreau C, Bévengut M, Dutschmann M (2008) The dual role of the orexin/hypocretin system in modulating wakefulness and respiratory drive. Curr Opin Pulm Med 14:512–518PubMedCrossRef
27.
go back to reference Nattie E (2000) Multiple sites for central chemoreception: their roles in response sensitivity and in sleep and wakefulness. Respir Physiol 122:223–235PubMedCrossRef Nattie E (2000) Multiple sites for central chemoreception: their roles in response sensitivity and in sleep and wakefulness. Respir Physiol 122:223–235PubMedCrossRef
28.
go back to reference Williams RH, Jensen LT, Verkhratsky A, Fugger L, Burdakov D (2007) Control of hypothalamic orexin neurons by acid and CO2. Proc Natl Acad Sci USA 104:10685–10690PubMedCrossRef Williams RH, Jensen LT, Verkhratsky A, Fugger L, Burdakov D (2007) Control of hypothalamic orexin neurons by acid and CO2. Proc Natl Acad Sci USA 104:10685–10690PubMedCrossRef
29.
go back to reference Sunanaga J, Deng BS, Zhang W, Kanmura Y, Kuwaki T (2009) CO2 activates orexin-containing neurons in mice. Respir Physiol Neurobiol 166:184–6PubMedCrossRef Sunanaga J, Deng BS, Zhang W, Kanmura Y, Kuwaki T (2009) CO2 activates orexin-containing neurons in mice. Respir Physiol Neurobiol 166:184–6PubMedCrossRef
30.
go back to reference Dutschmann M, Kron M, Mörschel M, Gestreau C (2007) Activation of Orexin B receptors in the pontine Kölliker-Fuse nucleus modulates pre-inspiratory hypoglossal motor activity in rat. Respir Physiol Neurobiol 159:232–235PubMedCrossRef Dutschmann M, Kron M, Mörschel M, Gestreau C (2007) Activation of Orexin B receptors in the pontine Kölliker-Fuse nucleus modulates pre-inspiratory hypoglossal motor activity in rat. Respir Physiol Neurobiol 159:232–235PubMedCrossRef
31.
go back to reference Zhang W, Shimoyama M, Fukuda Y, Kuwaki T (2006) Multiple components of the defense response depend on orexin: evidence from orexin knockout mice and orexin neuron-ablated mice. Auton Neurosci 126–127:139–145PubMedCrossRef Zhang W, Shimoyama M, Fukuda Y, Kuwaki T (2006) Multiple components of the defense response depend on orexin: evidence from orexin knockout mice and orexin neuron-ablated mice. Auton Neurosci 126–127:139–145PubMedCrossRef
32.
go back to reference Terada J, Nakamura A, Zhang W, Yanagisawa M, Kuriyama T, Fukuda Y, Kuwaki T (2008) Ventilatory long-term facilitation in mice can be observed during both sleep and wake periods and depends on orexin. J Appl Physiol 104:499–507PubMedCrossRef Terada J, Nakamura A, Zhang W, Yanagisawa M, Kuriyama T, Fukuda Y, Kuwaki T (2008) Ventilatory long-term facilitation in mice can be observed during both sleep and wake periods and depends on orexin. J Appl Physiol 104:499–507PubMedCrossRef
33.
go back to reference Strohl KP, Cherniack NS, Gothe B (1986) Physiologic basis of therapy for sleep apnea. Am Rev Respir Dis 134:791–802PubMed Strohl KP, Cherniack NS, Gothe B (1986) Physiologic basis of therapy for sleep apnea. Am Rev Respir Dis 134:791–802PubMed
34.
go back to reference Schiffman PL, Trontell MC, Mazar MF, Edelman NH (1983) Sleep deprivation decreases ventilatory response to CO2 but not load compensation. Chest 84:695–698PubMedCrossRef Schiffman PL, Trontell MC, Mazar MF, Edelman NH (1983) Sleep deprivation decreases ventilatory response to CO2 but not load compensation. Chest 84:695–698PubMedCrossRef
35.
go back to reference Han F, Chen E, Wei H, He Q, Ding D, Strohl KP (2001) Treatment effects on carbon dioxide retention in patients with obstructive sleep apnea–hypopnea syndrome. Chest 119:1814–1819PubMedCrossRef Han F, Chen E, Wei H, He Q, Ding D, Strohl KP (2001) Treatment effects on carbon dioxide retention in patients with obstructive sleep apnea–hypopnea syndrome. Chest 119:1814–1819PubMedCrossRef
36.
go back to reference Zhang Q, He QY, Du QY, Pang GF, Zhao LS, Wu RQ, Han F, Liu LC, Wang Y, Sun GX, Liu XY, Zhao ZW (2003) Epidemiologic study on sleep apnea-hypopnea syndrome by home investigation in Chengde city. Zhonghua Jie He He Hu Xi Za Zhi 26(5):273–275, ChinesePubMed Zhang Q, He QY, Du QY, Pang GF, Zhao LS, Wu RQ, Han F, Liu LC, Wang Y, Sun GX, Liu XY, Zhao ZW (2003) Epidemiologic study on sleep apnea-hypopnea syndrome by home investigation in Chengde city. Zhonghua Jie He He Hu Xi Za Zhi 26(5):273–275, ChinesePubMed
37.
go back to reference Fontana A, Gast H, Reith W, Recher M, Birchler T, Bassetti CL (2010) Narcolepsy: autoimmunity, effector T cell activation due to infection, or T cell independent, major histocompatibility complex class II induced neuronal loss? Brain 133:1300–1311PubMedCrossRef Fontana A, Gast H, Reith W, Recher M, Birchler T, Bassetti CL (2010) Narcolepsy: autoimmunity, effector T cell activation due to infection, or T cell independent, major histocompatibility complex class II induced neuronal loss? Brain 133:1300–1311PubMedCrossRef
Metadata
Title
Respiratory regulation in narcolepsy
Author
Fang Han
Publication date
01-03-2012
Publisher
Springer-Verlag
Published in
Sleep and Breathing / Issue 1/2012
Print ISSN: 1520-9512
Electronic ISSN: 1522-1709
DOI
https://doi.org/10.1007/s11325-011-0489-x

Other articles of this Issue 1/2012

Sleep and Breathing 1/2012 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.